Antivenom efficacy or effectiveness: The Australian experience

Toxicology

Volumn 268, Issue 3, 2010, Pages 148-154

  Isbister, Geoffrey K ^a,b  

^a CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^b MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

Antivenom; Coagulopathy; Effectiveness; Efficacy; Snake envenoming; Venom

Indexed keywords

ANTISERUM; PLACEBO; SCORPION VENOM; SNAKE VENOM; SNAKE VENOM ANTISERUM; SPIDER VENOM; SPIDER VENOM ANTISERUM;

AUSTRALIA; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TREATMENT FAILURE; ENVENOMATION; HUMAN; NEUROTOXICITY; NONHUMAN; POISONOUS SCORPION; POISONOUS SNAKE; POISONOUS SPIDER; PRIMARY PREVENTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SNAKEBITE;

ANIMALS; ANTIVENINS; ARACHNIDISM; AUSTRALIA; BITES AND STINGS; BLOOD COAGULATION DISORDERS; CNIDARIAN VENOMS; ELAPID VENOMS; HUMANS; SNAKE BITES; SNAKE VENOMS; TREATMENT OUTCOME;

ANIMALIA; CUBOZOA; DIPLURIDAE; ELAPIDAE; LATRODECTUS HASSELTI; SCORPIONES; STORERIA DEKAYI; VIPERINAE;

EID: 77049107081     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2009.09.013     Document Type: Review

References (77)

1. Abroug F., Elatrous S., Nouira S., Haguiga H., Touzi N., and Bouchoucha S. Serotherapy in scorpion envenomation: a randomised controlled trial. Lancet 354 9182 (1999) 906-909
2. Amaral C.F., and Rezende N.A. Treatment of scorpion envenoming should include both a potent specific antivenom and support of vital functions. Toxicon 38 8 (2000) 1005-1007
3. Ariaratnam C.A., Sjostrom L., Raziek Z., Kularatne S.A., Arachchi R.W., Sheriff M.H., Theakston R.D., and Warrell D.A. An open, randomized comparative trial of two antivenoms for the treatment of envenoming by Sri Lankan Russell's viper (Daboia russelii russelii). Transactions of the Royal Society of Tropical Medicine & Hygiene 95 1 (2001) 74-80
4. Barrett R., and Little M. Five years of snake envenoming in far north Queensland. Emergency Medicine (Fremantle) 15 5-6 (2003) 500-510
5. Boyer L.V., Seifert S.A., and Cain J.S. Recurrence phenomena after immunoglobulin therapy for snake envenomations. Part 2. Guidelines for clinical management with crotaline Fab antivenom. Annals of Emergency Medicine 37 2 (2001) 196-201 ([Review] [35 refs])
6. Boyer L.V., Theodorou A.A., Berg R.A., Mallie J., Chavez-Mendez A., Garcia-Ubbelohde W., Hardiman S., and Alagon A. Antivenom for critically ill children with neurotoxicity from scorpion stings. New England Journal of Medicine 360 20 (2009) 2090-2098
7. Calderon-Aranda E.S., Dehesa-Davila M., Chavez-Haro A., and Possani L.D. Scorpion stings and their treatment in mexico. In: Bon C., and Goyffon M. (Eds). Envenomings and their Treatments. 1st edn. (1995), Institute Pasteur, Paris 311-320
8. Chippaux J.-P., and Goyffon M. Venoms, antivenoms and immunotherapy. Toxicon 36 6 (1998) 823-846
9. Currie B.J. Snakebite in tropical Australia, Papua New Guinea and Irian Jaya. Emergency Medicine 12 (2000) 285-294
10. Currie B.J. Marine antivenoms. Journal of Toxicology: Clinical Toxicology 41 3 (2003) 301-308
11. Currie B.J. Treatment of snakebite in Australia: the current evidence base and questions requiring collaborative multicentre prospective studies. Toxicon 48 7 (2006) 941-956
12. Currie B.J., and Jacups S.P. Prospective study of Chironex fleckeri and other box jellyfish stings in the "Top End" of Australia's Northern Territory. Medical Journal of Australia 183 11-12 (2005) 631-636
13. Dart R.C., Seifert S.A., and Boyer L.V. A randomized multicenter trial of crotalinae polyvalent immune Fab (Ovine) antivenom for the treatment for crotaline snakebite in the United States. Archives of Internal Medicine 161 (2001) 2030-2036
14. Ellis R.M., Sprivulis P.C., Jelinek G.A., Banham N.D., Wood S.V., Wilkes G.J., Siegmund A., and Roberts B.L. A double-blind, randomized trial of intravenous versus intramuscular antivenom for Red-back spider envenoming. Emergency Medicine Australasian 17 2 (2005) 152-156
15. Graudins A., Padula M., Broady K., and Nicholson G.M. Red-back spider (Latrodectus hasselti) antivenom prevents the toxicity of widow spider venoms. Annals of Emergency Medicine 37 2 (2001) 154-160
16. Gueron M., and Ilia R. Is antivenom the most successful therapy in scorpion victims?. Toxicon 37 12 (1999) 1655-1657
17. Gutierrez J.M., Leon G., and Lomonte B. Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation. Clinical Pharmacokinetics 42 8 (2003) 721-741
18. Gutierrez J.M., and Rucavado A. Snake venom metalloproteinases: their role in the pathogenesis of local tissue damage. Biochimie 82 9-10 (2000) 841-850
19. Hartman L.J., and Sutherland S.K. Funnel-web spider (Atrax robustus) antivenom in the treatment of human envenomation. Medical Journal of Australia 141 12-13 (1984) 796-799
20. Hati R., Mitra P., Sarker S., and Bhattacharyya K.K. Snake venom hemorrhagins. Critical Reviews in Toxicology 29 1 (1999) 1-19
21. Hawgood B.J. Doctor Albert Calmette 1863-1933: founder of antivenomous serotherapy and of antituberculous BCG vaccination. Toxicon 37 9 (1999) 1241-1258
22. Henderson A., Baldwin L.N., and May C. Fatal brown snake (Pseudonaja textilis) envenomation despite the use of antivenom. Medical Journal of Australia 158 10 (1993) 709-710
23. Isbister G.K. Failure of intramuscular antivenom in redback spider envenomation. Emergency Medicine 14 4 (2002) 436-439
24. Isbister G.K. Clinical trials in toxinology: more than a discussion between friends?. Emergency Medicine Australasian 18 1 (2006) 4-6
25. Isbister G.K. Procoagulant snake toxins: laboratory studies, diagnosis, and understanding snakebite coagulopathy. Seminars in Thrombosis and Hemostasis 35 1 (2009) 93-103
26. Isbister G.K., Brown S.G., MacDonald E., White J., and Currie B.J. Current use of Australian snake antivenoms and frequency of immediate-type hypersensitivity reactions and anaphylaxis. Medical Journal of Australia 188 8 (2008) 473-476
27. Isbister G.K., Brown S.G., Miller M., Tankel A., MacDonald E., Stokes B., Ellis R., Nagree Y., Wilkes G.J., James R., Short A., and Holdgate A. A randomised controlled trial of intramuscular vs. intravenous antivenom for latrodectism-the RAVE study. QJM 101 7 (2008) 557-565
28. Isbister G.K., and Currie B.J. Suspected snakebite: one year prospective study of emergency department presentations. Emergency Medicine (Fremantle) 15 2 (2003) 160-169
29. Isbister G.K., Brown S.G.A., and Duffull S.B. Failure of antivenom to improve recovery in Australian snakebite coagulopathy. QJM 102 8 (2009) 563-568
30. Isbister G.K., Graudins A., White J., and Warrell D. Antivenom treatment in arachnidism. Journal of Toxicology: Clinical Toxicology 41 3 (2003) 291-300
31. Isbister G.K., Gray M.R., Balit C.R., Raven R.J., Stokes B.J., Porges K., Tankel A.S., Turner E., White J., and Fisher M.M. Funnel-web spider bite: a systematic review of recorded clinical cases. Medical Journal of Australia 182 8 (2005) 407-411
32. Isbister G.K., and Kiernan M.C. Neurotoxic marine poisoning. Lancet Neurology 4 4 (2005) 219-228
33. Isbister G.K., Little M., Cull G., McCoubrie D., Lawton P., Szabo F., Kennedy J., Trethewy C., Luxton G., Brown S.G., and Currie B.J. Thrombotic microangiopathy from Australian brown snake (Pseudonaja) envenoming. Internal Medicine Journal 37 8 (2007) 523-528
34. Isbister G.K., O'Leary M., Miller M., Brown S.G., Ramasamy S., James R., and Schneider J.S. A comparison of serum antivenom concentrations after intravenous and intramuscular administration of redback (widow) spider antivenom. British Journal of Clinical Pharmacology 65 1 (2008) 139-143
35. Isbister G.K., O'Leary M.A., Schneider J.J., Brown S.G., and Currie B.J. Efficacy of antivenom against the procoagulant effect of Australian brown snake (Pseudonaja sp.) venom: in vivo and in vitro studies. Toxicon 49 1 (2007) 57-67
36. Isbister G.K., Williams V., Brown S.G., White J., and Currie B.J. Clinically applicable laboratory end-points for treating snakebite coagulopathy. Pathology 38 6 (2006) 568-572
37. Ismail M., and Abd-Elsalam M.A. Pharmacokinetics of 125I-labelled IgG, F(ab′)2 and Fab fractions of scorpion and snake antivenins: merits and potential for therapeutic use. Toxicon 36 11 (1998) 1523-1528
38. Kasturiratne A., Wickremasinghe A.R., de Silva N., Gunawardena N.K., Pathmeswaran A., Premaratna R., Savioli L., Lalloo D.G., and de Silva H.J. The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Medicine 5 11 (2008) e218
39. Konstantakopoulos N., Isbister G.K., Seymour J.E., and Hodgson W.C. A cell-based assay for screening of antidotes to, and antivenom against Chironex fleckeri (box jellyfish) venom. Journal of Pharmacological and Toxicological Methods 59 3 (2009) 166-170
40. Kularatne S.A. Common krait (Bungarus caeruleus) bite in Anuradhapura, Sri Lanka: a prospective clinical study, 1996-98. Postgraduate Medical Journal 78 919 (2002) 276-280
41. Kuruppu S., Smith A.I., Isbister G.K., and Hodgson W.C. Neurotoxins from Australo-Papuan elapids: a biochemical and pharmacological perspective. Critical Reviews in Toxicology 38 1 (2008) 73-86
42. Laing G.D., Yarleque A., Marcelo A., Rodriguez E., Warrell D.A., and Theakston R.D. Preclinical testing of three South American antivenoms against the venoms of five medically-important Peruvian snake venoms. Toxicon 44 1 (2004) 103-106
43. Lalloo D.G., and Theakston R.D. Snake antivenoms. Journal of Toxicology: Clinical Toxicology 41 3 (2003) 277-290
44. Lalloo D.G., Theakston R.D., and Warrell D.A. The African challenge. Lancet 359 9316 (2002) 1527
45. Lalloo D.G., Trevett A.J., Korinhona A., Nwokolo N., Laurenson I.F., Paul M., Black J., Naraqi S., Mavo B., and Saweri A. Snake bites by the Papuan taipan (Oxyuranus scutellatus canni): paralysis, hemostatic and electrocardiographic abnormalities, and effects of antivenom. American Journal of Tropical Medicine & Hygiene 52 6 (1995) 525-531
46. Lalloo D.G., Trevett A.J., Owens D., Minei J., Naraqi S., Saweri A., Hutton R.A., Theakston R.D., and Warrell D.A. Coagulopathy following bites by the Papuan taipan (Oxyuranus scutellatus canni). Blood Coagulation & Fibrinolysis 6 1 (1995) 65-72
47. Madaras F., Mirtschin P.J., and Kuchel T. Antivenom development in Australia. Toxin Reviews 24 (2005) 79-94
48. Masci P.P., Mirtschin P.J., Nias T.N., Turnbull R.K., Kuchel T.R., and Whitaker A.N. Brown snakes (Pseudonaja genus): venom yields, prothrombin activator neutralization and implications affecting antivenom usage. Anaesthesia and Intensive Care 26 3 (1998) 276-281
49. Mebs D., and Ownby C.L. Myotoxic components of snake venoms: their biochemical and biological activities. Pharmacology and Therapeutics 48 2 (1990) 223-236
50. Meier J. Venomous and poisonous animals-a biologist's view. In: Meier J., and White J. (Eds). Clinical Toxicology of Animal Venoms and Poisons. 1st edn. (1995), CRC Press, Boca Raton 1-8
51. Myint L., Warrell D.A., Phillips R.E., Tin N.S., Tun P., and Maung M.L. Bites by Russell's viper (Vipera russelli siamensis) in Burma: haemostatic, vascular, and renal disturbances and response to treatment. Lancet 2 8467 (1985) 1259-1264
52. Nicholson G.M., and Graudins A. Spiders of medical importance in the Asia-Pacific: atracotoxin, latrotoxin and related spider neurotoxins. Clinical and Experimental Pharmacology and Physiology 29 9 (2002) 785-794
53. O'Leary, M. A., Brown, S. G. A., Jacoby, T., Gan, M., Schneider, J., Isbister, G. K. 2008. A sensitive and specific enzyme immunoassay to distinguish between two closely related Australian elapids: Tropidechis carinatus and Notechis scutatus, 8th Asia Pacific Congress of Animal, Plant and Microbial Toxins, Vietnam.
54. O'Leary M.A., and Isbister G.K. Commercial monovalent antivenoms in Australia are polyvalent. Toxicon 54 2 (2009) 192-195
55. O'Leary M.A., Isbister G.K., Schneider J.J., Brown S.G., and Currie B.J. Enzyme immunoassays in brown snake (Pseudonaja spp.) envenoming: detecting venom, antivenom and venom-antivenom complexes. Toxicon 48 1 (2006) 4-11
56. O'Leary M.A., Schneider J.J., Krishnan B.P., Lavis C., McKendry A., Ong L.K., and Isbister G.K. Cross-neutralisation of Australian brown and tiger snake venoms with commercial antivenoms: cross-reactivity or antivenom mixtures?. Toxicon 50 2 (2007) 206-213
57. Otero R., Leon G., Gutierrez J.M., Rojas G., Toro M.F., Barona J., Rodriguez V., Diaz A., Nunez V., Quintana J.C., Ayala S., Mosquera D., Conrado L.L., Fernandez D., Arroyo Y., Paniagua C.A., Lopez M., Ospina C.E., Alzate C., Fernandez J., Meza J.J., Silva J.F., Ramirez P., Fabra P.E., Ramirez E., Cordoba E., Arrieta A.B., Warrell D.A., and Theakston R.D. Efficacy and safety of two whole IgG polyvalent antivenoms, refined by caprylic acid fractionation with or without beta-propiolactone, in the treatment of Bothrops asper bites in Colombia. Transactions of the Royal Society of Tropical Medicine & Hygiene 100 12 (2006) 1173-1182
58. Paul V., Pratibha S., Prahlad K.A., Earali J., Francis S., and Lewis F. High-dose anti-snake venom versus low-dose anti-snake venom in the treatment of poisonous snake bites-a critical study. Journal of the Association of Physicians of India 52 (2004) 14-17
59. Phillips R.E., Theakston R.D., Warrell D.A., Galigedara Y., Abeysekera D.T., Dissanayaka P., Hutton R.A., and Aloysius D.J. Paralysis, rhabdomyolysis and haemolysis caused by bites of Russell's viper (Vipera russelli pulchella) in Sri Lanka: failure of Indian (Haffkine) antivenom. Quarterly Journal of Medicine 68 257 (1988) 691-715
60. Pochanugool C., Wilde H., Jitapunkul S., and Limthongkul S. Spontaneous recovery from severe neurotoxic envenoming by a Malayan krait Bungarus candidus (Linnaeus) in Thailand. Wilderness & Environmental Medicine 8 4 (1997) 223-225
61. Ramasamy S., Isbister G.K., Seymour J.E., and Hodgson W.C. The in vivo cardiovascular effects of box jellyfish Chironex fleckeri venom in rats: efficacy of pre-treatment with antivenom, verapamil and magnesium sulphate. Toxicon 43 6 (2004) 685-690
62. Ramos-Cerrillo B., de Roodt A.R., Chippaux J.P., Olguin L., Casasola A., Guzman G., Paniagua-Solis J., Alagon A., and Stock R.P. Characterization of a new polyvalent antivenom (Antivipmyn((R)) Africa) against African vipers and elapids. Toxicon (2008)
63. Smalligan R., Cole J., Brito N., Laing G.D., Mertz B.L., Manock S., Maudlin J., Quist B., Holland G., Nelson S., Lalloo D.G., Rivadeneira G., Barragan M.E., Dolley D., Eddleston M., Warrell D.A., and Theakston R.D. Crotaline snake bite in the Ecuadorian Amazon: randomised double blind comparative trial of three South American polyspecific antivenoms. British Medical Journal 329 7475 (2004) 1129
64. Sprivulis P., Jelinek G.A., and Marshall L. Efficacy and potency of antivenoms in neutralizing the procoagulant effects of Australian snake venoms in dog and human plasma. Anaesthesia and Intensive Care 24 3 (1996) 379-381
65. Tanos P.P., Isbister G.K., Lalloo D.G., Kirkpatrick C.M., and Duffull S.B. A model for venom-induced consumptive coagulopathy in snake bite. Toxicon 52 7 (2008) 769-780
66. Theakston R.D., Phillips R.E., Warrell D.A., Galagedera Y., Abeysekera D.T., Dissanayaka P., de Silva A., and Aloysius D.J. Envenoming by the common krait (Bungarus caeruleus) and Sri Lankan cobra (Naja naja naja): efficacy and complications of therapy with Haffkine antivenom. Transactions of the Royal Society of Tropical Medicine & Hygiene 84 2 (1990) 301-308
67. Tibballs J., and Sutherland S. The efficacy of antivenom in prevention of cardiovascular depression and coagulopathy induced by brown snake (Pseudonaja) species venom. Anaesthesia and Intensive Care 19 4 (1991) 530-534
68. Trevett A.J., Lalloo D.G., Nwokolo N.C., Naraqi S., Kevau I.H., Theakston R.D., and Warrell D.A. The efficacy of antivenom in the treatment of bites by the Papuan taipan (Oxyuranus scutellatus canni). Transactions of the Royal Society of Tropical Medicine & Hygiene 89 3 (1995) 322-325
69. Vetter R.S., and Isbister G.K. Medical aspects of spider bites. Annual Review of Entomology 53 (2008) 409-429
70. Warrell D.A., Davidson N.M., Greenwood B.M., Ormerod L.D., Pope H.M., Watkins B.J., and Prentice C.R. Poisoning by bites of the saw-scaled or carpet viper (Echis carinatus) in Nigeria. Quarterly Journal of Medicine 46 181 (1977) 33-62
71. Warrell D.A., Greenwood B.M., Davidson N.M., Ormerod L.D., and Prentice C.R. Necrosis, haemorrhage and complement depletion following bites by the spitting cobra (Naja nigricollis). Quarterly Journal of Medicine 45 177 (1976) 1-22
72. White J. CSL Antivenom Handbook. 2nd edn. (2001), CSL Ltd., Melbourne
73. White J., Warrell D., Eddleston M., Currie B.J., Whyte I.M., and Isbister G.K. Clinical toxinology-where are we now?. Journal of Toxicology: Clinical Toxicology 41 3 (2003) 263-276
74. Wiener S. Redback spider bite in Australia: an analysis of 167 cases. Medical Journal of Australia II (1961) 44-49
75. Winter K.L., Isbister G.K., Jacoby T., Seymour J.E., and Hodgson W.C. An in vivo comparison of the efficacy of CSL box jellyfish antivenom with antibodies raised against nematocyst-derived Chironex fleckeri venom. Toxicology Letters 187 2 (2009) 94-98
76. Yeung J.M., Little M., Murray L.M., Jelinek G.A., and Daly F.F. Antivenom dosing in 35 patients with severe brown snake (Pseudonaja) envenoming in Western Australia over 10 years. Medical Journal of Australia 181 11-12 (2004) 703-705
77. Zar M.A., Ebong O., and Bateman D.N. Effect of metoclopramide in guinea-pig ileum longitudinal muscle: evidence against dopamine-mediation. Gut 23 1 (1982) 66-70